In breast cancer, overexpression of HER2 is linked to what prognosis?

The association between HER2 overexpression in breast cancer and poor prognosis is well-documented in the medical literature. HER2 (human epidermal growth factor receptor 2) is a protein that, when overexpressed, promotes aggressive tumor growth and can lead to more advanced disease at diagnosis. Patients with HER2-positive breast cancer often experience a more aggressive form of the disease, which can be reflected in lower overall survival rates and a higher likelihood of recurrence compared to those with HER2-negative tumors.

Advancements in treatment, such as targeted therapies like trastuzumab (Herceptin), have improved outcomes for patients with HER2-positive breast cancer. However, despite these advancements, the intrinsic aggressiveness associated with HER2 overexpression still correlates with a more challenging prognosis. This is why the correct choice indicates that HER2 overexpression is linked to a poor prognosis, highlighting the importance of timely and effective management of HER2-positive breast cancers.